HAGENS BERMAN, National Trial Attorney, encourages Revance Therapeutics (RVNC) investors who have suffered significant losses to contact the company’s attorney to serve as the lead plaintiff in the securities fraud class action – QNT Press Release


San Francisco, December 18, 2021 (Global News Agency)-Hagens Berman urges Revance Therapeutics, Inc. (Nasdaq:RVNC) Investors suffered heavy losses Submit your loss immediately.

class time: November 25, 2019 – October 11, 2021
Deadline for lead plaintiff: February 8, 2022
access: www.hbsslaw.com/investor-fraud/RVNC
Contact a lawyer immediately: RVNC@hbsslaw.com

Revance Therapeutics, Inc. (RVNC) Securities Class Action:

The complaint alleges that the defendant misrepresented and omitted important facts related to the manufacturing and regulatory approval of Revance’s main product drug candidate DAXI for the treatment of frown lines.

Specifically, the defendant concealed: (i) The company’s manufacturing plant for DAXI had quality control defects; (ii) the above…

The full story can be found on Benzinga.com


Source link

Recommended For You

About the Author: News Center